Related Experiment Videos

Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect

Hangyuan Guo1, Haitao Lv, Weiliang Tang

  • 1Department of Cardiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing City, Zhejiang, 312000, China. ghangyuan@hotmail.com

Cardiovascular Drugs and Therapy
|August 25, 2012
PubMed
Abstract

Insights

Rosuvastatin improves insulin resistance and inhibits atherogenesis in mice by enhancing liver insulin signaling, independent of its cholesterol-lowering effects. This study investigates its impact on key metabolic pathways.

Area of Science:

  • Cardiovascular Research
  • Metabolic Syndrome Research
  • Pharmacology

Background:

  • Insulin resistance and atherogenesis are significant health concerns.
  • Statins, like rosuvastatin, are primarily known for cholesterol reduction.
  • Their potential effects on insulin signaling and atherogenesis require further investigation.

Purpose of the Study:

  • To evaluate rosuvastatin's efficacy in improving insulin resistance.
  • To determine if rosuvastatin inhibits atherogenesis by modulating insulin signaling.
  • To ascertain if these effects are independent of rosuvastatin's lipid-lowering properties.

Main Methods:

  • Utilized low-density lipoprotein receptor deficient mice fed a high-fat, high-fructose diet.
  • Administered rosuvastatin and mevalonic acid to different groups.
  • Assessed fasting glucose, insulin, lipid levels, aortic morphology, and key protein expressions in the liver.

Main Results:

  • High-fat, high-fructose diet significantly increased blood sugar and insulin.
  • Rosuvastatin and mevalonic acid treatments reduced aortic concentrations.
  • Both treatments elevated the expression of insulin receptor substrate 2, p-IRS2, Akt, p-Akt, and GLUT4 in the liver.

Conclusions:

  • Rosuvastatin improves insulin resistance and inhibits atherogenesis in mice.
  • The mechanism involves partially restoring the insulin-stimulated IRS2/PI3K/Akt/GLUT4 pathway in the liver.
  • These beneficial effects are independent of rosuvastatin's cholesterol-lowering action.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...